Tres Alchemix, a pioneering biotechnology company specializing in artificial intelligence (AI) drug discovery, has announced the successful closure of a $4.4 million [¥650 million] Series A financing round. The investment was led by DNX Ventures, with support from existing investor Waseda University Ventures. According to Tres Alchemix, the funds will be utilized to accelerate the development of…
No responses yet